Physician profile
Lisa Nesline
NPI 1225792757
$4,734.66
in general payments reported to CMS, 2019-2025
24 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $815 · 2023: $1,451 · 2024: $1,323 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,919.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.44 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $530.36 | 2022-2025 | Entyvio |
| Qol Medical, LLC | $442.38 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.93 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $281.45 | 2023-2025 | Stelara, Tremfya |
| Aimmune Therapeutics, INC. | $154.04 | 2024-2025 | Zenpep |
| Medtronic, INC. | $151.94 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $141.78 | 2022-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $139.08 | 2022-2023 | |
| Vivus LLC | $110.73 | 2024-2025 | Qsymia |
| Intercept Pharmaceuticals, INC. | $104.46 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $87.79 | 2025 | Iqirvo |
| Ardelyx, INC. | $87.25 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $83.50 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $80.00 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $51.02 | 2022-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $38.70 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $33.79 | 2023-2024 | Linzess |
| Evoke Pharma, INC. | $33.39 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $24.27 | 2024 | Dupixent |
| Exact Sciences Corporation | $22.32 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.02 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $17.93 | 2023 | Idacio |
| Lilly USA, LLC | $16.09 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Nesline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.